Rocket Pharmaceuticals (NASDAQ: RCKT) appoints new Principal Accounting Officer
Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
Rhea-AI Filing Summary
Rocket Pharmaceuticals, Inc. announced leadership changes in its finance organization. John Militello, VP of Finance, Senior Controller, Treasurer and Principal Accounting Officer, has resigned effective July 7, 2026 to pursue other opportunities. Joseph Manhede, currently Associate Vice President, Corporate Controller, will become Principal Accounting Officer effective July 8, 2026.
Manhede, age 48, joined Rocket in April 2026 and previously held senior finance roles at Outlook Therapeutics, Amneal Pharmaceuticals, Unilife Corporation and Celator Pharmaceuticals after starting his career at Deloitte. He is a CPA with an MBA from Holy Family University. The company states there are no new compensatory arrangements or related-party transactions tied to his designation.
Positive
- None.
Negative
- None.
Insights
Rocket executes a routine but important transition in its principal accounting role.
Rocket Pharmaceuticals is transitioning its Principal Accounting Officer role from John Militello to internal candidate Joseph Manhede, who has extensive public-company finance and SEC reporting experience. The change takes effect immediately after Militello’s departure in early July 2026, providing continuity.
Manhede’s background spans controllership, SOX compliance, IPO readiness and acquisition integration at multiple biopharma companies, plus Big Four audit experience and a CPA credential. With no new compensation arrangements or related-party transactions disclosed, this appears to be a standard leadership rotation focused on sustaining reporting and control functions.
